This research assesses the use of prescription stimulants (commonly used for the treatment of attention-deficit/hyperactivity disorder, narcolepsy, and excessive daytime sleepiness) in the Massachusetts Medicaid (MassHealth) population. The research investigated the average doses, member age, diagnoses, and medication formulations. It was concluded that the average daily dose of stimulants in the MassHealth population was below the FDA-approved maximum daily doses. The research was presented at the 2022 American Drug Utilization Review Society (ADURS) Symposium, an annual conference specializing in medication utilization within state Medicaid programs. The ADURS Symposium was held from February 24 through 26, 2022, in Scottsdale, Arizona.
Poster
Characterization of Stimulant Utilization in a State Medicaid Population
Mark Tesell, PharmD, BCPS
Kimberly Lenz, PharmD, MBA, FAMCP
Senior Pharmacy Director, MassHealth/Office of Clinical Affairs
Thomas Pomfret, PharmD, MPH, BCPS
Clinical Consultant Pharmacist Team Lead and Residency Program Director, Clinical Pharmacy Services
